The ultimate objective of the research projects in this program application is to improve our understanding of, and our therapeutic options in, chronic lymphocytic leukemia (CLL) through a coordinated investigation of the genetics, biochemistry, immunology and pharmacology of the disease and the associations between these biological parameters and clinical outcomes, including time from diagnosis to initial therapeutic intervention, response to therapy, time to progression, and overall survival. To achieve this, results of laboratory studies will be integrated into the clinical studies in a timely fashion. Important to the success of this project the collaboration with members of the Biostatistics core, who will provide assistance in the design and analysis of the clinical and laboratory research projects, as well as assist in designing the further exploration of promoting laboratory correlative findings in the CLL database assembled through this program project. The purpose of the Biostatistics Core (Core B) is to provide the following services that will be utilized by all the research projects. 1. To provide biostatistical collaboration for clinical research protocols. This includes all aspects of the design, conduct, analysis, and reporting of the clinical studies. 2. To provide biostatistical collaboration for all laboratory studies. This includes all aspects of the design, conduct, analysis, and reporting of such studies, including the coordination of laboratory results with parameters and outcomes from the clinical studies. 3. To advise on the database structure, to assure easy flow of data and into and out of the database analysis. 4. To assist in the supervision of data management, both at the central facility and at the institutional level, to maintain an accurate and complete computerized database. 5. To participate in the quality assurance of the data collected through an ongoing audit process. 6. To participate in the internal scientific review of projects proposed using the laboratory and clinical information contained in the database, as well as the tissue banking resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA081534-01
Application #
6259054
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-05-01
Project End
2000-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95
Maji, Santanu; Samal, Sabindra K; Pattanaik, Laxmipriya et al. (2015) Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 6:16623-37
Wu, Bainan; Barile, Elisa; De, Surya K et al. (2015) High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Curr Top Med Chem 15:2032-42
Wu, Bainan; Wang, Si; De, Surya K et al. (2015) Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol 22:876-887
Lamothe, Betty; Cervantes-Gomez, Fabiola; Sivina, Mariela et al. (2015) Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125:407-10
Laganà, Alessandro; Acunzo, Mario; Romano, Giulia et al. (2014) miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 42:5416-25
McClanahan, Fabienne; Gribben, John (2014) Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? Hematol Oncol Clin North Am 28:1055-71
Barile, Elisa; De, Surya K; Feng, Yongmei et al. (2013) Synthesis and SAR studies of dual AKT/NF-?B inhibitors against melanoma. Chem Biol Drug Des 82:520-533
Vamos, Mitchell; Welsh, Kate; Finlay, Darren et al. (2013) Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol 8:725-32
Hudson, Robert S; Yi, Ming; Volfovsky, Natalia et al. (2013) Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Mol Cancer 12:13

Showing the most recent 10 out of 46 publications